Adagene

ADAG57

Penny Stock

$2.40arrow_drop_up6.66%$0.15

Penny Stock

ADAG57

$2.40

arrow_drop_up6.66%$0.15

Penny Stock

Performance History

Key Stats
Open	$2.25
Prev. Close	$2.25
EPS	-0.72
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$106.24M
PE Ratio	-

	LOW	HIGH
Day Range	2.20	2.40
52 Week Range	1.20	4.38

Ratios







EPS	-0.72

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Adagene (ADAG)

Adagene Inc., also known as ADAG, is a biotechnology company that specializes in the discovery and development of antibody-based therapies. The company is focused on creating innovative treatments for cancer and other diseases by harnessing the power of the immune system. ADAG's scientists are at the forefront of research in the field of immuno-oncology, using their expertise to engineer therapeutic antibodies that can selectively target cancer cells while sparing healthy cells.

ADAG's stock price history has shown significant growth in recent years, reflecting the company's success in advancing its pipeline of drug candidates. Investors have been attracted to the potential of ADAG's novel approach to cancer treatment, which has generated excitement within the biotech industry. The stock has performed well compared to the broader market, with strong returns for shareholders.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Peter P. Luo Ph.D.
Headquarters: Suzhou
Employees: 248
Exchange: NASDAQ

Keep an eye on Adagene

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Adagene's (ADAG) price per share?

The current price per share for Adagene (ADAG) is $2.4. The stock has seen a price change of $0.15 recently, indicating a 6.67% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Adagene (ADAG)?

For Adagene (ADAG), the 52-week high is $4.38, which is 82.5% from the current price. The 52-week low is $1.21, the current price is 98.51% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Adagene (ADAG) a growth stock?

Adagene (ADAG) has shown an average price growth of 0.41% over the past three years. It has received a score of 39 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Adagene as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Adagene (ADAG) stock price performance year to date (YTD)?

As of the latest data, Adagene (ADAG) has a year-to-date price change of 22.45%. Over the past month, the stock has experienced a price change of -4.76%. Over the last three months, the change has been -22.08%. Over the past six months, the figure is -8.05%.

help

Is Adagene (ADAG) a profitable company?

Adagene (ADAG) has a net income of -$18.95M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -4.53K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $18.11M, with a revenue growth rate of 94.9%, providing insight into the company's sales performance and growth. The gross profit is $18.11M. Operating income is noted at -$27.2M. Furthermore, the EBITDA is -$36.13M.

help

What is the market capitalization of Adagene (ADAG)?

Adagene (ADAG) has a market capitalization of $106.25M. The average daily trading volume is 153.79K, indicating the stock's liquidity and investor engagement.

News

METASTATIC MICROSATELLITE-STABLE COLORECTAL CANCER

7/12/2024

Adagene Announces Poster Presentation on Masked Anti-CTLA-4 - GlobeNewswire

Adagene to Present at Investor Conferences in June

CALENDAR OF EVENTS

CONFERENCE CALLS/ WEBCASTS

5/22/2024

Adagene to Present at Investor Conferences in June

Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update

EARNINGS RELEASES AND OPERATING RESULTS

3/29/2024

Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update

Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board

DIRECTORS AND OFFICERS

3/7/2024

Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board

Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)

HEALTH

PRODUCT / SERVICES ANNOUNCEMENT

2/9/2024

Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)